$BLUE
bluebird bio, Inc.

2013 Q4 Form 10-Q Financial Statement

#000119312513442121 Filed on November 14, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $6.335M $6.385M $85.00K
YoY Change 7352.94% 7411.76%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.700M $3.800M $1.600M
YoY Change 88.0% 137.5%
% of Gross Profit
Research & Development $9.800M $8.706M $3.501M
YoY Change 50.77% 148.67%
% of Gross Profit
Depreciation & Amortization $330.0K $310.0K $80.00K
YoY Change 266.67% 287.5%
% of Gross Profit
Operating Expenses $14.50M $8.706M $3.501M
YoY Change 61.11% 148.67%
Operating Profit -$8.115M -$6.157M -$5.024M
YoY Change -9.39% 22.55%
Interest Expense $0.00 $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $44.00K -$17.00K
YoY Change -358.82%
Pretax Income -$8.100M -$6.113M -$5.000M
YoY Change -10.0% 22.26%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.081M -$6.113M -$5.041M
YoY Change -10.19% 21.27%
Net Earnings / Revenue -127.56% -95.74% -5930.59%
Basic Earnings Per Share -$0.26 $1.15
Diluted Earnings Per Share -$338.9K -$0.26 $1.14
COMMON SHARES
Basic Shares Outstanding 23.78M shares 23.62M shares 275.0K shares
Diluted Shares Outstanding 23.62M shares 554.0K shares

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $206.3M $216.8M
YoY Change
Cash & Equivalents $206.3M $216.8M $74.02M
Short-Term Investments $0.00
Other Short-Term Assets $5.700M $4.700M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $212.0M $221.5M
YoY Change 212.74%
LONG-TERM ASSETS
Property, Plant & Equipment $10.92M $5.392M
YoY Change 747.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.483M $1.400M
YoY Change
Total Long-Term Assets $12.40M $6.795M
YoY Change 706.44%
TOTAL ASSETS
Total Short-Term Assets $212.0M $221.5M
Total Long-Term Assets $12.40M $6.795M
Total Assets $224.4M $228.3M
YoY Change 223.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.359M $1.144M
YoY Change 100.6%
Accrued Expenses $4.900M $5.000M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $34.87M $31.49M
YoY Change 653.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $208.0K $39.10M
YoY Change
Total Long-Term Liabilities $208.0K $39.10M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $34.87M $31.49M
Total Long-Term Liabilities $208.0K $39.10M
Total Liabilities $72.72M $70.56M
YoY Change 1290.76%
SHAREHOLDERS EQUITY
Retained Earnings -$98.68M -$90.59M
YoY Change 34.52%
Common Stock $239.0K $236.0K
YoY Change 7866.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $151.7M $157.7M
YoY Change
Total Liabilities & Shareholders Equity $224.4M $228.3M
YoY Change 223.69%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$8.081M -$6.113M -$5.041M
YoY Change -10.19% 21.27%
Depreciation, Depletion And Amortization $330.0K $310.0K $80.00K
YoY Change 266.67% 287.5%
Cash From Operating Activities -$5.460M -$8.860M -$4.220M
YoY Change -17.65% 109.95%
INVESTING ACTIVITIES
Capital Expenditures -$5.290M -$2.110M -$40.00K
YoY Change 1369.44% 5175.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $100.0K $0.00
YoY Change
Cash From Investing Activities -$5.290M -$2.010M -$40.00K
YoY Change 1369.44% 4925.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 230.0K -1.180M 59.86M
YoY Change -1250.0% -101.97%
NET CHANGE
Cash From Operating Activities -5.460M -8.860M -4.220M
Cash From Investing Activities -5.290M -2.010M -40.00K
Cash From Financing Activities 230.0K -1.180M 59.86M
Net Change In Cash -10.52M -12.05M 55.60M
YoY Change 50.07% -121.67%
FREE CASH FLOW
Cash From Operating Activities -$5.460M -$8.860M -$4.220M
Capital Expenditures -$5.290M -$2.110M -$40.00K
Free Cash Flow -$170.0K -$6.750M -$4.180M
YoY Change -97.29% 61.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23780211 shares
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
24209000
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74018000
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23633000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1336000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23633000 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.41
CY2013Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
440000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3977000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.41
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73354000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3977000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.06
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2582000
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
248058000
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1144000
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2739000
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
31490000
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
12155000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
157700000
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2821000
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90594000
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25340000
CY2013Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2529000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
236000
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
228262000
CY2013Q3 us-gaap Liabilities
Liabilities
70562000
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2659000
CY2013Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
36543000
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1253000
CY2013Q3 us-gaap Assets Current
AssetsCurrent
221467000
CY2013Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1403000
CY2013Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
216791000
CY2013Q3 us-gaap Assets
Assets
228262000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
216791000
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4676000
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10379000
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5392000
CY2013Q3 blue Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5006000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25604000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
309000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
309000 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.09
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2201000 shares
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6512000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21511000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-55747000
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
215000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
15267000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2173000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4628000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
340000
CY2012Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
215000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
46000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69322000
CY2012Q4 us-gaap Liabilities
Liabilities
5229000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
340000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Assets Current
AssetsCurrent
67784000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
250000
CY2012Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
67011000
CY2012Q4 us-gaap Assets
Assets
69322000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67011000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
773000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1288000
CY2012Q4 blue Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2115000
dei Trading Symbol
TradingSymbol
BLUE
dei Entity Registrant Name
EntityRegistrantName
bluebird bio, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001293971
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8786000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.96
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Description of the business</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> bluebird bio, Inc. (the &#x201C;Company&#x201D;) was incorporated in Delaware on April&#xA0;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company was formed to develop, manufacture and market therapies to safely and effectively deliver genes useful in the treatment of serious human diseases. Since its inception, the Company has devoted substantially all of its resources to its development efforts relating to its product candidates, including activities to manufacture product in compliance with good manufacturing practices (&#x201C;GMP&#x201D;), preparing to conduct clinical studies of its product candidates, providing general and administrative support for these operations and protecting its intellectual property.</p> </div>
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.12
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
48905000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1855000 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8786000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
42000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
37000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.79
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4506000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: stock-based compensation expense, accrued expenses, valuation of warrants, revenue and income taxes.</p> </div>
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-23114000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
11000
us-gaap Revenues
Revenues
13846000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3903000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17240000
us-gaap Contracts Revenue
ContractsRevenue
13542000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1347000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17240000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-408000
us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
655000
us-gaap Investment Income Interest
InvestmentIncomeInterest
21000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17240000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16832000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-2000
us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
1153000
us-gaap Net Income Loss
NetIncomeLoss
-17240000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
122177000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3380000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
304000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3981000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
440000
us-gaap Costs And Expenses
CostsAndExpenses
30678000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9441000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
105408000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
92000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
61203000
us-gaap Share Based Compensation
ShareBasedCompensation
4833000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
610000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
149780000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1021000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4533000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
104972000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21237000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
92000
us-gaap Proceeds From Sale And Collection Of Notes Receivable
ProceedsFromSaleAndCollectionOfNotesReceivable
344000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Income Loss
NetIncomeLoss
-14672000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
511000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
255000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
59859000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
784000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-67000
us-gaap Costs And Expenses
CostsAndExpenses
15015000
blue Stock Issued During Period Shares Stock Options Exercised1
StockIssuedDuringPeriodSharesStockOptionsExercised1
37000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.44
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
551000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
95000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.44
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14408000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
250000 shares
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
206000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
629000 shares
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
18000
us-gaap Revenues
Revenues
255000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
218000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14672000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
111000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
88000
us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
394000
us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
2337000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
243000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14760000
us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
40000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4302000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59867000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-255000
us-gaap Share Based Compensation
ShareBasedCompensation
570000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
205000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
48414000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-755000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2955000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10713000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
3057000
us-gaap Participating Securities Distributed And Undistributed Earnings
ParticipatingSecuritiesDistributedAndUndistributedEarnings
5274000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3506000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
blue Participating Securities Distributed And Undistributed Earnings Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsDiluted
5142000
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P9Y
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P5Y
CY2013Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2015-03-31
CY2013Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0527 pure
CY2013Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
209000
CY2013Q2 blue Letter Of Credit Related With New Lease Agreement
LetterOfCreditRelatedWithNewLeaseAgreement
1253000
CY2013Q2 blue Rent Abatement Credits
RentAbatementCredits
209000
CY2013Q2 blue Area Of Leased Space
AreaOfLeasedSpace
43600 sqft
CY2013Q2 blue Landlord Contribution For Leasehold Improvements
LandlordContributionForLeaseholdImprovements
6538000
CY2013Q2 us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
655000
CY2013Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
104921000
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.14
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
554000 shares
CY2012Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
95000 shares
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.15
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
275000 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
184000 shares
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
629000 shares
CY2012Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4000
CY2012Q3 us-gaap Revenues
Revenues
85000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5041000
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
315000
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
632000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5024000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-5041000
CY2012Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
85000
CY2012Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
22000
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
5109000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1608000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3836000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2516000
CY2012Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-23114000
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
185000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3501000
CY2012Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
487000
CY2012Q3 us-gaap Participating Securities Distributed And Undistributed Earnings
ParticipatingSecuritiesDistributedAndUndistributedEarnings
17271000
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8706000
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23623000 shares
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4506000 shares
CY2013Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
33000
CY2012Q3 blue Participating Securities Distributed And Undistributed Earnings Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsDiluted
16954000
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23623000 shares
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2013Q3 us-gaap Revenues
Revenues
6385000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6113000
CY2013Q3 us-gaap Contracts Revenue
ContractsRevenue
6251000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6113000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
44000
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
11000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6113000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6157000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-6113000
CY2013Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
134000
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
12542000

Files In Submission

Name View Source Status
0001193125-13-442121-index-headers.html Edgar Link pending
0001193125-13-442121-index.html Edgar Link pending
0001193125-13-442121.txt Edgar Link pending
0001193125-13-442121-xbrl.zip Edgar Link pending
blue-20130930.xml Edgar Link completed
blue-20130930.xsd Edgar Link pending
blue-20130930_cal.xml Edgar Link unprocessable
blue-20130930_def.xml Edgar Link unprocessable
blue-20130930_lab.xml Edgar Link unprocessable
blue-20130930_pre.xml Edgar Link unprocessable
d593256d10q.htm Edgar Link pending
d593256dex101.htm Edgar Link pending
d593256dex102.htm Edgar Link pending
d593256dex311.htm Edgar Link pending
d593256dex312.htm Edgar Link pending
d593256dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g593256cm342.jpg Edgar Link pending
g593256cm363.jpg Edgar Link pending
g593256cm364.jpg Edgar Link pending
g593256cm365.jpg Edgar Link pending
g593256cm366.jpg Edgar Link pending
g593256cm367.jpg Edgar Link pending
g593256cm368.jpg Edgar Link pending
g593256cm369.jpg Edgar Link pending
g593256cm370.jpg Edgar Link pending
g593256g26p95.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending